Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 24Urinary Bladder Neoplasms 5Neoplasms 2Urothelial Bladder Cancer 1Urologic Neoplasms 1Urinary Bladder Diseases 1Stomach Neoplasms 1Recurrence 1Prostate cancer, familial 1Parotid Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Lung Neoplasms 1Genetic Predisposition to Disease 1Driving Under the Influence 1Disease Progression 1Disease 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Multiparametric Magnetic Resonance Imaging × Clear all
NCT06999174 2025-07-02

Multiparametric MRI for Characterization of Hepatocellular Carcinoma

University Hospital Muenster

Recruiting
128 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡